Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214628 · ClinicalTrials.gov registry record · Phase 2
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
A Phase 2 study, sponsored by Ophthotech Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT02214628: Clinical Trial Phase 2 study, sponsored by Ophthotech Corporation.
NCT02214628 is a Phase 2 study that was terminated before completion, run by Ophthotech Corporation. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02214628, a Phase 2 study, was terminated before completion, sponsored by Ophthotech Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
Interventions
- DRUG Fovista® (anti-PDGF BB) plus anti-VEGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02214628
The ClinicalTrials.gov registry entry for NCT02214628 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthotech Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fovista® (anti-PDGF BB) plus anti-VEGF is the first listed.
NCT02214628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02214628 about?
NCT02214628 is a clinical study titled "Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD". The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
What is the current status of trial NCT02214628?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2014-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02214628?
The interventions under investigation include: Fovista® (anti-PDGF BB) plus anti-VEGF (DRUG).
Who is sponsoring clinical trial NCT02214628?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.